

December 17, 2025

Company name: Hoky Medical Co., Ltd.
President: Hideki Kawakubo, President and CEO
Securities code: 3593 (Tokyo Stock Exchange, Prime Market)
Inquiries: Taisuke Fujita, Executive Vice President and CFO
(Tel: +81-3-6229-1300)

Notice Regarding Revision of Dividend Forecast (No Dividends) and Abolition of Shareholder Benefit Program

At a meeting of its Board of Directors held today, Hoky Medical Co., Ltd. (the “Company”) resolved to forgo dividend payments for the third quarter and year-end of the fiscal year ending March 31, 2026 and to abolish the shareholder benefit program from the fiscal year ending March 31, 2027, subject to the successful completion of the tender offer for the Company’s common shares (the “Company Shares”) by TCG 2509 Co., Ltd. (the “Tender Offer”), as disclosed in today’s separate press release titled, “Notice Regarding Expression of Opinion in Support of Tender Offer for Company Shares by TCG 2509 Co., Ltd. and Recommendation to Tender” (the “Expression of Opinion Press Release”). Details are provided below.

1. Revision of dividend forecast (no dividend)

(1) Reason for the revision of dividend forecast (ordinary dividend)

At a meeting of the Board of Directors held today, the Company resolved to express its opinion in support of the Tender Offer and to recommend that the Company’s shareholders tender their shares in the Tender Offer.

This resolution was adopted on the premise that the Company Shares are expected to be delisted following the completion of the Tender Offer and related subsequent procedures (for details, please refer to the Expression of Opinion Press Release).

The Company has long positioned shareholder returns as a key management priority and has sought to enhance shareholder returns through progressive dividends and share repurchase. However, because economic differences may arise between shareholders who tender their shares in the Tender Offer and those who do not, the Company, from the perspective of ensuring fairness among shareholders, resolved at today’s Board meeting to forgo dividend payments for the third quarter and year-end of the fiscal year ending March 31, 2026, subject to the successful completion of the Tender Offer.

If it becomes clear that the Tender Offer will not be successful, the Company will promptly determine its future dividend policy (including dividends for the fiscal year ending March 31, 2026) and issue a notice regarding the revision of the dividend forecast.

(2) Details of the revision

	Annual dividend (yen)				
	End-Q1	End-Q2	End-Q3	Year-end	Total
Previous forecast (announced on Oct. 27, 2025)			23.75	23.75	47.50
Revised forecast			00.00	00.00	00.00
Dividends paid in the current fiscal year	23.75	23.75			
Dividends paid in the previous fiscal year (ended March 31, 2025)	20.00	20.00	20.00	20.00	80.00

2. Abolition of the shareholder benefit program

For the reasons described in “(1) Reason for the revision of dividend forecast (ordinary dividend)” under “1. Revision of dividend forecast (no dividend),” the Company resolved at today’s Board meeting to abolish the Company’s shareholder benefit program starting from the fiscal year ending March 31, 2027, subject to the successful completion of the Tender Offer. If the Tender Offer is successfully completed, the shareholder benefit granted to shareholders holding 100 shares (one unit) or more who are listed or recorded in the Company’s shareholder registry as of September 30, 2025 will be the final benefit provided under such program, after which such program will be terminated. If the Tender Offer is not successfully completed, the Company will consider the future handling of the shareholder benefit program together with its dividend policy, as noted in “(1) Reason for the revision of dividend forecast (ordinary dividend)” under “1. Revision of dividend forecast (no dividend)” above, and will make an announcement upon promptly reaching a decision.